NVO vs VKTX

Novo Nordisk (NVO) remains a formidable pharmaceutical giant, leading in diabetes and obesity care with its dominant GLP-1 franchise. The company is financially robust, boasts significant proprietary assets, and has a strategic vision for new therapeutic applications and AI integration. Recent FDA approvals for Wegovy HD and oral Wegovy are positive developments, enhancing its product portfolio. H...

Viking Therapeutics maintains its strong 10x growth potential, with no material changes since the last analysis warranting a significant score adjustment. The company's lead asset, VK2735, a dual GLP-1/GIP agonist, continues to be a compelling candidate in the lucrative metabolic disorder market. Positive Phase 2 data for both injectable and oral formulations positions it as a potential best-in-cl...